ArticleNanomedicine : nanotechnology, biology, and medicine2018
Nanoliposomal delivery of cytosolic phospholipase A
Article in Nanomedicine : nanotechnology, biology, and medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Pirin Transcriptionally Regulates PLA2G4A To Inhibit Ferroptosis in Colorectal Cancer via Lipid Profile Remodeling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanotherapy for Cancer and Biological Activities of Green Synthesized AgNPs Using AqueousPharmaceuticals (Basel, Switzerland) · 2024Article
- Application of Nanotechnology and Phytochemicals in Anticancer Therapy.Pharmaceutics · 2024Review
- Nanotechnology-Based Drug Delivery Systems in the Transdermal Treatment of Melanoma.Advanced pharmaceutical bulletin · 2023Review
- Deep learning classification of uveal melanoma based on histopathological images and identification of a novel indicator for prognosis of patients.Biological procedures online · 2023Article
- Targeting WEE1/AKT Restores p53-Dependent Natural Killer-Cell Activation to Induce Immune Checkpoint Blockade Responses in "Cold" Melanoma.Cancer immunology research · 2022Article
- Targeting Protein Translation in Melanoma by Inhibiting EEF-2 Kinase Regulates Cholesterol Metabolism though SREBP2 to Inhibit Tumour Development.International journal of molecular sciences · 2022Article
- A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML.International journal of molecular sciences · 2021Article
- Activating Sphingosine-1-phospahte signaling in endothelial cells increases myosin light chain phosphorylation to decrease endothelial permeability thereby inhibiting cancer metastasis.Cancer letters · 2021Article
- Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy.Science translational medicine · 2021Article
- Development of a Novel Multi-Isoform ALDH Inhibitor Effective as an Antimelanoma Agent.Molecular cancer therapeutics · 2020Article
- Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery.Frontiers in oncology · 2020Article
- Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma.Nanomaterials (Basel, Switzerland) · 2019Review
- Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases ABiochimica et biophysica acta. Molecular and cell biology of lipids · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Drug resistance and toxicity are major limitations of cancer treatment and frequently occurs during melanoma therapy. Nanotechnology can decrease drug resistance by improving drug delivery, with limited toxicity. This study details the development of nanoparticles containing arachidonyl trifluoromethyl ketone (ATK), a cytosolic phospholipase A
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.